Figure 6.

Positive circulating tumor DNA (ctDNA) and short fragment size of plasma cell‐free DNA (cfDNA) were associated with poor prognosis. (Kaplan‐Meier method and log‐rank test). A,B, Prognosis was analyzed in 27 renal cell carcinoma (RCC) patients whose cfDNA samples were sequenced at pretreatment state. Association of ctDNA status (positive vs negative) for progression‐free survival (PFS) (A) and cancer‐specific survival (CSS) (B). C,D, Association of cfDNA fragment size using a microfluidics‐based platform between ≤166 bp (the prominent peak of the distribution of cfDNA fragments according to size) (short) and >166 bp (long) for PFS (C) and CSS (D). E,F, Prognosis was analyzed in 13 RCC patients with metastasis whose cfDNA samples were sequenced at pretreatment state as in A‐D. Association of ctDNA status (positive vs negative) (E) and cfDNA fragment size (short vs long) (F) for CSS